Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the ...

announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ: CERE) for violations of the securities laws and ...

announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for violations of the securities laws and ...

Large-cap public M&A is a hard business to break into, but Paul Hastings feels its build, along with the arrival of Schiele, ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

He recently served as Senior Vice President, Head of Global Regulatory and Access Solutions at Cerevel Therapeutics (Cerevel) ...

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

Emraclidine was an experimental treatment for schizophrenia and Alzheimer's that AbbVie obtained through its acquisition of Cerevel Therapeutics, along with other experimental drugs such as ...